High-quality APIs. Zero disruption.
Global reliability.
28–30 October 2025
Messe Frankfurt, GermanyOur Team at CPHI Frankfurt 2025
Deepak Sapra
CEO, Pharmaceutical Services & Active Ingredients
Nirav Shah
Vice President, and Head, API - North Asia
Karun Gaur
Vice President and Head, Strategic Projects API
Dr. A Kalyan Chakravarthy
Executive VP & Head – SEAMEA & B2B Formulations
Kalpesh
Vice President, and Head – EU Market, API & B2B Collaborations
Gustavo Mayrink De Castro Marques
Vice President and Head, API Sales & Marketing, LATAM
R Lalitha Kumari
Global Head of API Product Management & Head of Sales - US & Canada
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 250+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
-
250+ APIs
-
8 Manufacturing sites
-
1970+ drug master files across global markets.
-
Over 325 ANDAs
-
Filed 4500+ patents globally, out of which 1125 have been granted.
-
Experience with complex APIs and formulations supporting early market entries.
-
Preferred pharma API supplier for pharma companies in more than 80 countries.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
What we achieved in the past year:
Our Achievement (awards)
10/07/2025
CDP Recognition
05/08/2025
Tentative Approval for Generic Lumateperone capsules
25/04/2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
05/04/2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
05/12/2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
15/02/2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row
15/02/2023
S&P Global’s Sustainability Yearbook for the 3rd year
04/11/2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
07/10/2021
The winner of the Best Indian Company in the US - Manufacturing Sector for the year 2021
21/01/2021
Best Supply Chain Team of the Year - Pharma- 2021
03/11/2021
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2021
11/11/2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
19/10/2020
Dr. Reddy's recognized at the CPhI Pharma Awards 2020 as the winner in the category of ‘Excellence in Pharma: Sustainability’
03/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2020
05/11/2020
Dr. Reddy’s Laboratories wins “API Supplier of the Year” award at the Global Generics & Biosimilars Awards 2019
Our Plants
About CPHI Frankfurt 2025
This flagship global event brings together 2,400+ exhibitors, 62,000+ pharma professionals, and cutting-edge innovations across APIs, biopharma, contract services, packaging, machinery, and more. It’s where the world’s pharmaceutical leaders connect to unlock new opportunities, strengthen partnerships, and stay ahead in a rapidly shifting global market.
As part of this vibrant ecosystem, we’re excited to engage with peers, customers, and collaborators. We're here to create lasting value and help you if you're exploring dependable API partnerships, looking to scale your sourcing strategies, or seeking operational agility.
Let’s meet at CPHI Frankfurt. We’re ready to support your next phase of growth with reliable, agile, and future-ready API solutions.
免責事項
このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。
Let’s discuss API sourcing
Join us at Hall - 9.1 | Booth - B48